Catalent, Inc. (NYSE:CTLT) Receives $52.46 Consensus Price Target from Brokerages

Catalent, Inc. (NYSE:CTLT) has been given a consensus recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $52.46.

A number of equities research analysts have recently weighed in on the company. Barclays lifted their target price on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. StockNews.com began coverage on Catalent in a report on Friday, April 19th. They set a “sell” rating for the company. Stephens reaffirmed an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. UBS Group reaffirmed a “neutral” rating and issued a $63.50 price target (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th.

Institutional Trading of Catalent

Hedge funds and other institutional investors have recently made changes to their positions in the company. Gladius Capital Management LP bought a new stake in shares of Catalent during the third quarter worth about $28,000. Exchange Traded Concepts LLC bought a new stake in Catalent in the third quarter valued at approximately $31,000. GAMMA Investing LLC bought a new stake in Catalent in the fourth quarter valued at approximately $33,000. Cary Street Partners Investment Advisory LLC boosted its holdings in Catalent by 1,162.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after acquiring an additional 709 shares during the last quarter. Finally, Mather Group LLC. bought a new stake in Catalent in the first quarter valued at approximately $52,000.

Catalent Trading Down 0.1 %

CTLT stock opened at $56.01 on Friday. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company has a fifty day moving average price of $56.79 and a two-hundred day moving average price of $48.39. Catalent has a one year low of $31.45 and a one year high of $60.20. The stock has a market cap of $10.14 billion, a price-to-earnings ratio of -8.24, a price-to-earnings-growth ratio of 5.98 and a beta of 1.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the firm earned $0.62 earnings per share. The company’s revenue for the quarter was down 10.2% compared to the same quarter last year. Equities analysts anticipate that Catalent will post 0.28 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.